We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Targeting Skeletal Muscle Myosin ATPase May Reduce Resting Energy Waste in Heart Failure With Reduced Ejection Fraction

MedXY Editorial Team•May 6, 2026•Cardiology
HFrEFMavacamtenmyosin ATPase

Highlights

Patients with heart failure with reduced ejection fraction (HFrEF) showed higher resting skeletal muscle myosin ATP consumption than matched controls, supporting the concept that peripheral muscle energetics are intrinsically abnormal in this syndrome.

Proteomics identified distinct regulation of acetyl-lysine sites in HFrEF skeletal muscle, suggesting that post-translational remodeling may contribute to altered contractile protein behavior and inefficient energy use.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Optimizing Heart Failure with Reduced Ejection Fraction Management: Insights from Swedish Registry on Quadruple Therapy Adherence and PersistenceA Swedish cohort study reveals increased adoption and high adherence to quadruple pharmacotherapy in HFrEF, associating treatment persistence with better clinical outcomes and highlighting areas for improved dosing and continuation.Aug 27, 2026Personalized Risk Modeling of Interatrial Shunt Therapy in Heart Failure: Insights from the RELIEVE-HF TrialThe RELIEVE-HF trial reveals distinct predictors of outcomes after interatrial shunt implantation in HFrEF and HFpEF, enabling personalized risk modeling to identify patients likely to benefit from this therapy.Aug 15, 2026AI-Enabled ECG as a New Surveillance Tool for Left Ventricular Dysfunction in Hypertrophic Cardiomyopathy on MavacamtenThis study explores the potential of an AI-powered ECG tool to monitor left ventricular systolic dysfunction in hypertrophic cardiomyopathy patients treated with mavacamten, offering a less burdensome alternative to frequent echocardiogramsAug 12, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Mavacamten Achieves Surgical-Grade Hemodynamic Correction in Obstructive Hypertrophic Cardiomyopathy by Reversing the Anrep Response
A comparative pressure-volume analysis reveals that mavacamten and alcohol septal ablation produce equivalent hemodynamic improvements in obstructive HCM, primarily through reversal of the chronic Anrep response that drives elevated myocard
Apr 13, 2026
Only 1 in 5 Veterans with Heart Failure Achieve Recommended Quadruple Therapy Within 3 Years—What This Means for Clinical PracticeA large retrospective study of 52,850 veterans reveals that just 21.2% achieve guideline-directed quadruple therapy for HFrEF, with a median time of 197 days. Socioeconomic barriers, including prescription copays, emerge as critical modifiaApr 5, 2026
Residual Clinical Risk and Economic Burden in HFrEF: Insights from the Quadruple Medical Therapy EraThis review analyzes the real-world one-year outcomes and healthcare costs for HFrEF patients on quadruple therapy, revealing significant residual risk despite optimized pharmacologic management.Mar 15, 2026